Patricia Villagrasa
Overview
Explore the profile of Patricia Villagrasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Llombart-Cussac A, Perez-Garcia J, Braso-Maristany F, Pare L, Villacampa G, Gion M, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4123-4130.
PMID: 38995291
Purpose: The purpose of this study was to assess the predictive capability of HER2DX assay following (neo)adjuvant trastuzumab-pertuzumab (HP)-based therapy in HER2-positive (HER2+) early breast cancer. Experimental Design: HER2DX was...
2.
Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle A, Chic N, Braso-Maristany F, et al.
NPJ Breast Cancer
. 2024 Mar;
10(1):20.
PMID: 38448600
In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated...
3.
Conte B, Braso-Maristany F, Hernandez A, Pascual T, Villacampa G, Schettini F, et al.
EBioMedicine
. 2024 Mar;
102:105043.
PMID: 38447275
Background: Early-stage triple-negative breast cancer (TNBC) displays clinical and biological diversity. From a biological standpoint, immune infiltration plays a crucial role in TNBC prognosis. Currently, there is a lack of...
4.
Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):32.
PMID: 37120452
No abstract available.
5.
Waks A, Ogayo E, Pare L, Marin-Aguilera M, Braso-Maristany F, Galvan P, et al.
JAMA Oncol
. 2023 Apr;
9(6):835-840.
PMID: 37103927
Importance: Patients with early-stage ERBB2 (formerly HER2)-positive breast cancer (ERBB2+ BC) who experience a pathologic complete response (pCR) after receiving neoadjuvant therapy have favorable survival outcomes. Predicting the likelihood of...
6.
Bueno-Muino C, Echavarria I, Lopez-Tarruella S, Roche-Molina M, Del Monte-Millan M, Massarrah T, et al.
JAMA Oncol
. 2023 Apr;
9(6):841-846.
PMID: 37103916
Importance: Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed. Objective: To determine if use of...
7.
Prat A, Braso-Maristany F, Martinez-Saez O, Sanfeliu E, Xia Y, Bellet M, et al.
Nat Commun
. 2023 Mar;
14(1):1157.
PMID: 36859416
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question,...
8.
Tolaney S, Tarantino P, Graham N, Tayob N, Pare L, Villacampa G, et al.
Lancet Oncol
. 2023 Mar;
24(3):273-285.
PMID: 36858723
Background: We aimed to report on long-term outcomes of patients with small, node-negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and to establish potential biomarkers to predict prognosis....
9.
Braso-Maristany F, Griguolo G, Chic N, Pascual T, Pare L, Maues J, et al.
J Natl Cancer Inst
. 2022 Dec;
115(3):332-336.
PMID: 36576009
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right...
10.
Guarneri V, Bras-Maristany F, Dieci M, Griguolo G, Par L, Mar In-Aguilera M, et al.
EBioMedicine
. 2022 Nov;
85:104320.
PMID: 36374768
Background: HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures (immune, proliferation, luminal differentiation and HER2...